Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats

Citation
H. Azuma et al., Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats, J AM S NEPH, 12(6), 2001, pp. 1280-1292
Citations number
48
Categorie Soggetti
Urology & Nephrology","da verificare
Journal title
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
ISSN journal
10466673 → ACNP
Volume
12
Issue
6
Year of publication
2001
Pages
1280 - 1292
Database
ISI
SICI code
1046-6673(200106)12:6<1280:HGFPTD>2.0.ZU;2-8
Abstract
Long-term renal isografts in humans and laboratory animals exhibit features similar to those of chronic allograft nephropathy (CAN), indicating that a ntigen-independent factors, such as acute renal ischemia, are likely to be involved in the development of CAN. Hepatocyte growth factor (HGF) has been demonstrated to play a renotropic role in renal regeneration and protectio n from acute ischemic injury. This study was thus conducted to investigate the effect of HGF on the development of CAN, using an established rat model . HGF was administered daily (100 mug/d, intravenously) for 4 wk after engr aftment. Control animals received saline solution. Allografts from control animals exhibited early evidence of severe structural collapse and necrotic cell death in the proximal tubules and outer medulla, with mononuclear cel l infiltration, within 1 wk after engraftment. This was followed by sequent ial upregulation of adhesion molecules and cytokines, accompanied by dense macrophage infiltration Fibrogenic events, as indicated by marked increases in transforming growth factor-beta1 expression and the accumulation of smo oth muscle alpha -actin, occurred during the same period. Control animals u ltimately developed features typical of CAN, with functional deterioration and severe histologic changes; a survival rate of 50.6% by 32 wk was observ ed. in contrast, remarkably Little early injury and no late fibrogenic even ts were observed for the HGF-treated group. All treated animals survived, w ith well preserved graft function, during the 32-wk follow-up period. These results indicate that renal protection and recovery from early allograft i njury with HGF treatment greatly contribute to a reduction of susceptibilit y to the subsequent development of CAN in a rat model. The potential applic ation of HGF in the prevention of CAN warrants further attention.